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Prasong Hospital, Ubon Ratchathani, ThailandA B S T R A C TObjectives: To measure health-related quality of life (HRQOL) in Thai
HIV patients using the patient-generated index for HIV (PGI-HIV) and
to compare the psychometric properties of the PGI-HIV with those of
the EuroQol ﬁve-dimensional (EQ-5D) questionnaire and the Medical
Outcome Study HIV Health Survey in terms of practicality, reliability,
validity, and responsiveness. Methods: In this study, two rounds of
interviews were carried out in HIV outpatients who met the eligibility
criteria and attended the HIV Clinic of Warinchamrap Hospital
between January and March 2010. The patients were interviewed
using a data collection form and three HRQOL measures (the PGI-
HIV, the EQ-5D questionnaire, and the Medical Outcome Study HIV
Health Survey) to assess the practicality and validity. The second
interview was performed to check the test-retest reliability and
responsiveness. Results: A total of 210 patients completed the study.
They were mostly women (69.5%), with a mean age of 39.2  11.1
years. The majority with the US Centers for Disease Control and
Prevention clinical stage C took the current antiretroviral drugs withinee front matter Copyright & 2014, International S
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ndence to: Phantipa Sakthong, Faculty of Pharmace
i Road, Pathumwan, Bangkok 10330, Thailand.1 year. The average PGI score was about 0.60, implying HIV/AIDS and
antiretroviral drug therapy decreased the patients’ quality of life by
40% from their healthy life. Three mostly cited impact domains were
hyperlipidemia, lipid maldistribution and lipodystrophy, and hepati-
tis. The PGI-HIV was considered as practical, with a mean difﬁculty
score of 3.7  0.8, highly reliable (intraclass correlation coefﬁcient ¼
0.75; P o 0.001), and responsive to HRQOL changes (effect size ¼ 0.81;
standardized response mean ¼ 0.99), but not valid when compared
with CD4 levels and viral loads (all Pearson’ r o 0.2; P 4 0.05).
Conclusions: The PGI-HIV was used to measure the individual HRQOL
in a Thai sample of HIV-positive patients. It proves to be practical,
highly reliable, and very responsive to changes in patients’ HRQOL.
Keywords: HIV/AIDS, individual quality of life, patient-generated
index, psychometric properties, Thailand.
Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Human immunodeﬁciency virus (HIV) infection is a major public
health problem in Thailand and worldwide. The World Health
Organization in 2010 estimated that 3.3 million people live with
HIV and 1.8 million die from AIDS each year [1]. In Thailand, the
Minister of Public Health reported 372,874 patients diagnosed
with HIV/AIDS and 98,153 deaths of people from the disease up to
March 2011 [2]. HIV infection and its management have many
effects on not only patients’ survival but also their health-related
quality of life (HRQOL). Although Highly Active Antiretroviral
Therapy has a high potency to prolong HIV patients’ life expect-
ancy and decrease the number of deaths, it tends to cause
various adverse effects (i.e., adverse drug reactions and drug
interactions) and partly affect the daily activities, thereby reduc-
ing their quality of life [3]. Because patients need to rely on the
Highly Active Antiretroviral Therapy lifelong, the assessment of
HRQOL in this patient group is of paramount importance.
HRQOL assessments are usually carried out by applying stand-
ardized or individualized measures. In the case of HIV, most HRQOLevaluations make use of the standardized method in forms of
generic or disease-speciﬁc questionnaires. Some standardized
HRQOL instruments for HIV disease include the Medical Outcome
Study HIV Health Survey (MOS-HIV) [4], Quality of Well-Being
[5], human immunodeﬁciency virus-quality of life 31 questions [6],
HIV/AIDS-targeted quality of life [7], AIDS Health Assessment
Questionnaire [8], HIV Overview of Problems Evaluation System [9],
Multidimensional Quality of Life Questionnaire for HIV/AIDS [10],
Functional Assessment of Human Immunodeﬁciency Virus Infec-
tion [11], Euro-QoL [12], and World Health Organization’s Quality of
Life HIV instrument [13]. The Schedule for Evaluation of Individual
Quality of Life [14] is one of two individualized tools that have been
used. The other is the “patient-generated index (PGI)” [15], which is
widely used in many diseases and yet to be explored in HIV/AIDS.
In general, individualized HRQOL tools help individual patients to
identify their own impact domains and give a weight to each domain
themselves, whereas most standardized instruments provide pre-
determined items, each of which carries the same weight for all
patients. This is consistent with the deﬁnition of the World Health
Organization that “quality of life” is “the individuals’ perception ofociety for Pharmacoeconomics and Outcomes Research (ISPOR).
conﬂicts of interest with regard to the content of this article.
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systems in which they live, and in relation to their goals, expect-
ations, standards, and concerns” [16]. Accordingly, an individualized
tool should be more appropriate than a standardized measure to
assess patients’ quality of life from their own perspectives.
From an extensive information search, only one study in
Ireland reported an individualized quality of life tool (Schedule
for Evaluation of Individual Quality of Life-Direct Weight) to
monitor HIV patients [14]. To date, no study in this area has
used the PGI, although it is more speciﬁc than the Schedule for
Evaluation of Individual Quality of Life-Direct Weight in terms of
assessing the effects of disease and treatment [15]. The former
asks patients to identify the ﬁve domains most affected by their
disease and treatment, but the latter just requests them to write
down the ﬁve most important things in life, which are quite
general. In addition, the PGI’s psychometric properties were still
unclear, especially its responsiveness to HRQOL changes, and no
data on the psychometric properties of the PGI in HIV/AIDS were
available [17]. This study therefore aimed to measure the indi-
vidual quality of life in Thai patients with HIV/AIDS using the
patient-generated index for HIV (PGI-HIV) and to compare the
psychometric properties of the PGI-HIV with those of the EuroQol
ﬁve-dimensional (EQ-5D) questionnaire and the MOS-HIV in
terms of its practicality, reliability, validity, and responsiveness.
The MOS-HIV was chosen because it proves to be reliable and
valid for measuring the quality of life in Thai HIV patients [18].
The EQ-5D questionnaire was also selected owing to the recom-
mended health utility method in Thailand [19] and its high
validity in measuring health utility in Thai HIV patients [20].
Methods
This study was ethically approved by Warinchamrap Hospital in
Ubon Ratchathani Province. The hospital was selected in theA 19-year-old college student was diagnose
His parents passed away due to HIV 5 ye
grandparents.  He does not smoke, drink a
CDC clinical stage prior to the ARV treatm
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Fig. 1 – An example of the patient-generated index for HIV (Pstudy because it is a specialized center for HIV referral in the
northeast region of Thailand. The study with two rounds of
interviews (1 month apart) with HIV/AIDS outpatients was con-
ducted. Details of the methodology are elaborated below.
Patients and Eligibility Criteria
All 315 HIV patients attending the HIV clinic of the hospital from
January to March 2010, the time period of data collection, were
approached. Two hundred ten patients (67%), however, were
eligible for the study. The eligibility criteria were adults older
than 18 years, able to communicate in Thai, taking Highly Active
Antiretroviral Therapy regimens, and willing to participate in the
study with written informed consent. Regarding the sample size,
it was determined on the basis of the criterion validity test [21],
with the minimum correlation coefﬁcient (r) between MOS-HIV
scores and other variables of 0.25 or more, two-sided signiﬁcance
level (α/2 ¼ 0.25), and β ¼ 0.10. When taking the loss to follow-up
and withdrawal from the study (20%) into consideration, at least
200 patients were required.
Instruments
A data collection form was specially designed to gather data
relating to patients’ characteristics, HIV infection, medication
use, medication adherence (i.e., simple questions plus pill
counts), and relevant data. Three HRQOL tools were also included
as follows:
The PGI-HIV that embraced a three-column table and a
predetermined list of 30 health-related and 6 nonhealth domains
was devised from 20 HIV patients in the pilot test, along with
clinical experiences of the researcher (K.C.) and then checked for
content validity by two experts. To complete this HRQOL instru-
ment, patients were requested to go through three steps: 1) selectd as HIV infection at the age of 10. 
ars ago and he now lives with his 
lcohol, or use narcotic drugs.  His 
ent was identified as B3 and he has 
ivudine+nevirapine). The current 
 as 316 cells/µL and 50 copies/mL, 
 ratings and weights were recorded 
 the table below.  
tings on 
 0 (the 
s) to 100 
tus)
Domain weights 
for preferred 
improvement with 
a maximum of 12 
points
2/12 (= 0.167)
2/12 (= 0.167)
3/12 (= 0.25)  
3/12 (= 0.25)
0/12 (= 0)
2/12 (= 0.167)
67) + (0.5×0.25) + (0.4×0.25) +
 0.56
GI-HIV) score found in a Thai outpatient with HIV/AIDS.
Table 1 – Characteristics of HIV patients (N ¼ 210).
Characteristic Attribute Value
Age (y) Mean  SD 39.2  11.1
Range (min–max) 19–68
Sex, n (%) Male 64 (30.5)
Female 146 (69.5)
Marital status, n (%) Married 75 (35.7)
Single 8 (3.8)
Widowed 73 (34.8)
Divorced 54 (25.7)
Education, n (%) Elementary school 160 (76.2)
Secondary and high
school
38 (18.1)
University/college and
higher
12 (5.7)
Income (baht/mo),
n (%)
r2000 20 (9.5)
2001–4000 109 (51.9)
4001–6000 73 (34.8)
6001–8000 8 (3.8)
CDC clinical stage
before ARV therapy,
n (%)
A (asymptomatic,
acute HIV or PGL)
17 (8.1)
B (symptomatic
condition)
72 (34.3)
C (AIDS-indicator
condition)
121 (57.6)
Time since HIV
diagnosis (y)
Mean  SD 4.7  2.4
Type of ARV drugs,
n (%)
Stavudine þ
lamivudine þ
nevirapine (GPO-VIRS)
122 (58.1)
Zidovudine þ
lamivudine þ
nevirapine (GPO-
VIRZ)
40 (19.1)
Stavudine þ
lamivudine þ
efavirenz
33 (15.7)
Zidovudine þ
tenofovir þ lopinavir
þ ritonavir
15 (7.1)
Use of current ARV
drugs (mo)
Mean  SD 4.3  2.3
Number of ARV
tablets
Mean  SD 3.3  2.1
Medication adherence
by pill count
Mean  SD 96.4  2.6
CD4 cell counts
(cells/μL)
Mean  SD 457.6  246.4
Viral load (copies/mL) Mean  SD 0.09  0.29
ARV, antiretroviral; CDC, Centers for Disease Control and Preven-
tion; PGL, persistent generalized lymphadenopathy.
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by HIV/AIDS and antiretroviral (ARV) drug therapy from the list or
their own choices, and put them in column 1; 2) rate each of the
six domains on a scale of 0 (the worst status) to 100 (the best
status) in column 2 using a visual analogue scale as appropriate;
and 3) weigh each domain for preferred improvement in column
3 and total them up with a maximum of 12 points. There is no
need for patients to allocate points to every domain, but the total
points must be 12. The PGI-HIV score, which is the sum of the
multiplication products of domain ratings and weights, is
detailed in Fig. 1. The score ranges from 0 to 1; the higher the
score, the better patient’s quality of life.The MOS-HIV is a 35-item disease-speciﬁc questionnaire [22]
that consists of 11 domains, which can be further summarized as
Physical Health Summary score or Mental Health Summary score.
The 11 domain scores are within the range of 0 to 100, and the
two summary scores are 50  10. A higher score of the MOS-HIV
reﬂects better quality of life.
The EQ-5D questionnaire tool comprises ﬁve domains (i.e.,
mobility, self-care, usual activity, pain/discomfort, and anxiety/
depression), each of which has three levels: no problems, some
problems, and major problems. To answer this questionnaire,
patients were requested to pick a level that best describes their
current health for each domain. It should be noted that the
weights conﬁrmed in Thai people [23] were used in this study to
calculate EQ-5D questionnaire health utility index scores. These
scores normally range from 0.45 to 1.00, where 1.00 and 0
represent perfect health and death, respectively; negative values
indicate health status worse than death. It should be noted that
the Thai version of the MOS-HIV and the EQ-5D questionnaire
were available from Dr. Albert Wu and the EuroQol Group,
respectively.Data Collection
The 210 outpatients who met the eligibility criteria were inter-
viewed two times during two hospital visits. They were inter-
viewed by the researcher (K.C.) using three HRQOL tools for both
visits in the pharmacy counseling room. Each interview was
audiotaped with permission and subsequently transcribed to
cross-check all answers. This ﬁrst interview was intended to
measure the patients’ quality of life and to assess the tool’s
practicality and validity. For the second hospital visit, they were
interviewed by the same researcher so as to evaluate its test-
retest reliability and responsiveness. In this second interview,
patients were asked to answer the query, “Compared with the
previous visit, how would you rate your health in general now?”
with 5-point Likert scale answers: (1) much better, (2) slightly
better, (3) the same as before, (4) slightly worse, and (5) much
worse. If they picked answer (3), their three HRQOL scores would
be used to compute the test-retest reliability. For answers with
any changes in the health status (i.e., 1, 2, 4, or 5), their scores
would be analyzed for the responsiveness.Data Analysis
All data from two rounds of the interviews were entered into
PASW Statistics 18 (SPSS-IBM Co., Chicago, IL) and analyzed by
using descriptive statistics for patients’ characteristics and psy-
chometric properties. The practicality of the PGI-HIV, the EQ-5D
questionnaire, and the MOS-HIV was assessed in terms of the
interview time, refusal rate, and difﬁculty scores by a ﬁve-point
Likert scale, with lower scores indicating more difﬁculty. To
evaluate the test-retest reliability of the three HRQOL tools, an
intraclass correlation coefﬁcient (ICC) was calculated. Regarding
the criterion validity, Pearson’s correlation coefﬁcients (r)
between the PGI scores, the PHS or MHS scores of the MOS-HIV,
the EQ-5D questionnaire index scores, and clinical variables
including CD4 levels and viral loads were used.
The responsiveness of the three HRQOL tools was presented
as an effect size (ES) and standardized response means
(SRMs). The ES was computed using the mean change scores of
the three HRQOL tools between the ﬁrst and second visits divided
by the SD of the ﬁrst visit (or baseline data). If the mean change
scores were divided by the SD of the mean change, it would yield
the SRM. A signiﬁcance level in this study was determined at
α ¼ 0.05.
Table 2 – Descriptive statistics of three HRQOL tools (N ¼ 210).
Quality-of-life tool Mean  SD Range % Floor % Ceiling
PGI-HIV 0.61  0.16 0.06–0.95 0 0
EQ-5D questionnaire 0.56  0.26 0.45 to 1.00 1.0 11.9
MOS-HIV with 11 domains
General Health Perception 44.7  7.9 25.0–75.0 0 0
Physical Functioning 75.6  13.9 16.7–100.0 0 5.7
Role Functioning 84.3  26.2 0–100.0 2.0 71.4
Social Functioning 72.2  21.3 20.0–100.0 0 21.4
Cognitive Functioning 73.5  15.5 25.0–100.0 0 3.8
Pain 59.5  9.1 33.3–100.0 0 0.5
Mental Health 50.8  7.5 36.0–72.0 0 0.5
Energy/Vitality 50.9  8.5 30.0–80.0 0 0
Health Distress 59.4  21.1 15.0–100.0 0 1.0
Quality of Life 34.4  22.9 0–100.0 16.2 1.0
Health Transition 35.8  23.7 0–100.0 16.7 0.5
Physical Health Summary Score 48.4  4.6 30.6–56.9 0 0
Mental Health Summary Score 39.3  4.5 29.8–55.3 0 0
EQ-5D, EuroQol ﬁve-dimensional; HRQOL, health-related quality of life; MOS-HIV, Medical Outcome Study HIV Health Survey; PGI-HIV, patient-
generated index for HIV.
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A total of 210 HIV outpatients were enrolled in this study, and all
of them completed two rounds of the interviews. Most patients
were women (69.5%), and the mean age was 39.2  11.1 years.
Other patient characteristics and clinical details are given in
Table 1.Individual Quality of Life
Table 2 presents the descriptive statistics of the PGI-HIV, the EQ-
5D questionnaire, and the MOS-HIV. The mean PGI-HIV and EQ-
5D scores were equal to 0.61  0.16 and 0.56  0.26, respectively.
When considering high ceiling or ﬂoor effects by HRQOL scores
greater than 15% [24], neither was found in the EQ-5D question-
naire and the PGI-HIV measure. For the MOS-HIV, the mean PHS
and MHS scores were 48.4  4.6 and 39.3  4.5, respectively. The
high ceiling effects were detected in two domains, that is, Role
Function (71.4%) and Social Functioning (21.4%), and ﬂoor effects
in two domains, that is, Quality of Life (16.2%) and Health
Transition (16.7%). The mean PHS and MHS score was lower than
the norm scores of 50 10. Based on the ﬁrst visit, 30 health-
related domains impacted by HIV/AIDS and ARV drug therapy
were reported by patients (Table 3). Top 5 major impact domains
included hyperlipidemia (31.4%); lipid maldistribution and lip-
odystrophy (28.1%); hepatitis (26.2%); chronic fever, fatigue,
weight loss, or chronic diarrhea (25.7%); and severe drug allergy
and shock (25.2%). Moreover, six nonhealth impact domains were
identiﬁed. Examples were travel expenses for visiting the hospi-
tal, social unacceptance of HIV patients, and the dissemination of
HIV infection to their partner or family members.Psychometric Properties of the PGI-HIV
As shown in Table 4, for practicality among the three HRQOL
tools, the EQ-5D questionnaire had the shortest interviewing
time, followed by the PGI-HIV and the MOS-HIV, respectively.
No patient declined to be interviewed with the three HRQOL
tools. Most of them agreed that the PGI-HIV and the EQ-5D
questionnaire were easy to answer, compared with the MOS-
HIV. The test-retest reliability in 109 patients with the same
health status indicated that the EQ-5D questionnaire, the PHS ofthe MOS-HIV, and the PGI-HIV had high agreement, whereas the
MHS of the MOS-HIV had fair agreement (all P o 0.01).
When looking at the criterion validity, only the PHS of the
MOS-HIV was signiﬁcantly correlated with CD4 levels and viral
loads (P o 0.01), while the MHS of the MOS-HIV was signiﬁcantly
associated with viral loads (P o 0.05). Both the PGI-HIV and the
EQ-5D questionnaire were not signiﬁcantly related to both CD4
levels and viral loads. As for the responsiveness, 101 patients
responded some alterations to their health during the second
visit, but two answered “slightly worse” and no one opted for
“much worse.” Thus, the HRQOL scores of 99 patients were used
to compute “positive” responsiveness. It was found that the PGI-
HIV and the MHS of the MOS-HIV were highly responsive
whereas the EQ-5D questionnaire was small to medium respon-
sive, and the PHS of the MOS-HIV was very low responsive.Discussion
This is the ﬁrst study that reported the individual quality of life
using the PGI-HIV. The overall study mirrored the quality of life in
Thai HIV outpatients who were mostly female, middle-aged, and
less educated with low income. They largely suffered from full-
blown AIDS for a period of time, but just received the current ARV
drugs within 1 year, which was recent enough to elicit their views
on the quality of life. Although most patients had to take 28
tablets daily, they still adhered to their multiple drug usage,
therefore leading to increased CD4 cell counts and undetectable
viral load.
In this HIV patient group, the average PGI score was about
0.60. This implied that HIV/AIDS and ARV drug therapy probably
decreased the patients’ quality of life by 40% from their healthy
life. More than one quarter of the patients described that their
lives were mainly affected by adverse drug effects. A possible
explanation was that half of them were taking GPO-VIRS accord-
ing to the previous national guidelines as discussed by Phanu-
phak et al. [25]. The drug containing stavudine, lamivudine, and
nevirapine is likely to cause both hyperlipidemia and lipodys-
trophy, especially for stavudine, and nevirapine has the highest
incidence of hepatitis [26]. This combined ARV drug should be
replaced by GPO-VIRZ or tenofovir-containing regimens based on
the Thai National Guidelines 2010 [27], but profound anemia
caused by ziduvudine is still a matter of great concern. Apart
Table 3 – All domains impacted by HIV/AIDS and ARV drug therapy reported by HIV patients during the ﬁrst
visit (N ¼ 210).
Domain
Number of
reports (%)
Health-related domains
1. High blood lipid levels (hyperlipidemia) 66 (31.4)
2. Lipid maldistribution and lipodystrophy—fat deposits around the abdomen and neck, and thinning arms,
legs, face, and bum
59 (28.1)
3. Liver inﬂammation (hepatitis) 55 (26.2)
4. Chronic fever, fatigue, weight loss, or chronic diarrhea 54 (25.7)
5. Severe drug allergies and shock with hospitalization 53 (25.2)
6. Taking many medicines or difﬁculty in swallowing big tablets 52 (24.8)
7. Increased immunity or CD4 cell counts 51 (24.3)
8. Weight gain almost or near to normal 49 (23.3)
9. Being healthier 47 (22.4)
10. Numbness of hands and feet 44 (21.0)
11. Lung infection (pneumonia) 41 (19.5)
12. Feeling to be a patient with no value in life and easily tired 40 (19.1)
13. Fungal infection in the brain with severe headache, stiff neck, and tuberculosis (TB) 39 (18.6)
14. Decreased viral load until undetectable 38 (18.1)
15. Low red blood cells and hemoglobin (anemia) 37 (17.6)
16. Feeling disheartened to be HIV infected and need take medicines for life 37 (17.2)
17. Difﬁculty in seeping (insomnia) and nightmare 35 (16.7)
18. Oral thrush, sore throat, and painful swallowing 32 (15.2)
19. Itchy skin 30 (14.3)
20. Dizziness 27 (12.9)
21. Nausea, vomiting, or loss of appetite 19 (9.1)
22. Diarrhea or boasting 17 (8.1)
23. Hope to live on 17 (8.1)
24. Happiness for having sex 17 (8.1)
25. Medicines with bad taste, feeling bitter, or unpalatable eating 15 (7.1)
26. Herpes simplex or herpes zoster 13 (6.2)
27. Swollen lymph nodes in the neck, armpit, or groin 11 (5.2)
28. Headache 7 (3.3)
29. Skin disease or wounds taking long time to heal 5 (2.4)
30. Viral infection in the eyes causing vision problems 4 (1.9)
Nonhealth domains
1. Travel expenses for visiting the hospital and cost of living 39 (18.6)
2. Social unacceptance of HIV patients 37 (17.6)
3. Passing on HIV to the couple or family members 36 (17.1)
4. Responsible for taking care of the family and want to live with them as long as possible 35 (16.7)
5. Job loss, less productivity, or cannot go to school 34 (16.2)
6. Do not get help and support from the family 29 (13.8)
ARV, antiretroviral.
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and a large number of medicines had considerable effects on
patients’ quality of life.
With the result of 30 health-related domains, it was consis-
tent with the study of Hickey et al. [14] that applied the Schedule
for Evaluation of Individual Quality of Life to measure individual
quality of life in Ireland. They pointed out that most HIV patients
put the areas of health (71%) as a major impact, followed by
family (69%) and ﬁnancial issues (59%). Nevertheless, in the
present study, Thai patients were mostly worried about numer-
ous health-related problems and concerned about economic and
social aspects, possibly due to their low socioeconomic status
with monthly income lower than household nationwide earned
on average (20,903 baht or US $697) [28].
As regards the practicality, the PGI-HIV was construed as
difﬁcult and time-consuming, but second after the EQ-5D ques-
tionnaire; the MOS-HIV was the hardest. The reason might be
that patients needed to make a decision on six impact domains
with related ratings, and this cognitive skill was not normallypracticed in their daily life. Regarding the test-retest reliability of
the PGI-HIV, the ICC of 0.75 was considered as highly reliable (ICC
¼ 0.70–0.85) [17], consistent with the results of the EQ-5D ques-
tionnaire and the PHS of the MOS-HIV. This result was also
aligned with Haywood et al.’s study [29], which afﬁrmed the high
reliability of the PGI (ICC 4 0.80) in patients with ankylosing
spondylitis. As with the study, Martin et al. [17] reviewed the
psychometric properties of the PGI methods in 18 studies and
concluded that the PGI is markedly reliable and valid (i.e.,
Pearson’s or Spearman rank correlation coefﬁcients ¼ 0.30–0.49).
The ﬁndings of this present study were therefore corresponding
to their review in terms of high reliability but not for the validity.
As for the criterion validity of the PGI, our study found no
associations between the PGI and CD4 levels and viral loads, and
neither did the EQ-5D questionnaire. Only the MOS-HIV had
associations with these HIV clinical variables. A possible explan-
ation for this is that the PGI measured concepts different from
those of the MOS-HIV. For example, from the PGI results, most
HIV patients were concerned about their adverse drug effects of
Table 4 – Psychometric properties of the PGI-HIV compared with those of the EQ-5D questionnaire and the MOS-
HIV.
Psychometric property PGI-HIV EQ-5D questionnaire PHS MHS
Practicality (N ¼ 210)
Interview time (min), mean  SD 14.6  4.4 5.9  1.7 20.9  5.3
Refusal rate, % 0 0 0
Ease of use, n (%) 84 (40.0) 83 (39.5) 10 (4.8)
Difﬁculty rating scores, mean  SD 3.7  0.8 4.2  0.9 2.4  0.7
Reliability (N ¼ 109)
Intraclass correlation coefﬁcients 0.75† 0.89† 0.87† 0.37†
Criterion validity (N ¼ 210)
CD4 levels, r 0.07 0.06 0.31† 0.08
Viral loads, r 0.08 0.04 0.38† 0.14*
Responsiveness in patients with “much better”
or “slightly better” health status (N ¼ 99)
Scores on visit 1, mean  SD 0.61  0.14 0.56  0.27 46.67  5.10 38.72  4.93
Scores on visit 2, mean  SD 0.73 (0.12) 0.61  0.26 46.74  4.40 42.42  4.27
Mean change, mean  SD 0.12  0.12) 0.05  0.12 0.07  2.71 3.70  4.54
Effect size (ES)‡ 0.81 0.21 0.01 0.75
Standardized response mean (SRM)§ 0.99 0.48 0.03 0.81
EQ-5D, EuroQol ﬁve-dimensional; MOS-HIV, Medical Outcome Study HIV Health Survey; PGI-HIV, patient-generated index for HIV; MHS, Mental
Health Summary; PHS, Physical Health Summary.
* Statistically signiﬁcant, P o 0.05.
† Statistically signiﬁcant, P o 0.01.
‡ ES ¼ Mean change  SD of PGI-HIV scores on visit 1.
§ SRM ¼ Mean change  SD of the mean change.
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general health in HIV patients. These patient concerns may not
be reﬂected from the values of CD4 levels and viral loads. The PGI
approach also measures nonhealth domains, which may not be
captured by the HIV clinical variables.
With respect to the responsiveness, the PGI-HIV was clearly
responsive to quality-of-life changes, as evidenced by the high
values of ES and SRM. The result also supported a PGI study in
patients with obstructive sleep apnea [30]. In the review of Martin
et al. [17], they reported that 13 of 18 studies reported that the PGI
was highly responsive (ES and SRM ¼ 0.5–0.8), but three articles
[31–33] disclosed no responsiveness (ES and SRM o 0.20); two
studies did not present the data. This present study hence
provided evidence for the high responsiveness.
Like the PGI-HIV, the MHS of the MOS-HIV were highly
responsive. The responsiveness indexes of the PHS of the MOS-
HIV and the EQ-5D questionnaire, however, were small. A
possible explanation is that the HIV patients who reported
improvement in their health were better in terms of mental
health. They were less fearful or concerned about their HIV
symptoms and adverse drug effects of ARV drugs, whereas their
physical health was still not much improved because the follow-
up visit was just 1 month. This duration may be too short to
assess the responsiveness of physical health in HIV patients. The
EQ-5D questionnaire also has four items related to physical
health (mobility, self-care, usual activity, and pain/discomfort).
This study had some limitations. Most patients did not get
used to the decision-making process and judgment in the PGI-
HIV. They felt uncomfortable with the selection of impact
domains and could rarely come up with a new set of domains.
As a result, this study could not provide an exhaustive list of
domains for the PGI-HIV. In addition, they found it difﬁcult to use
a visual analogue scale of 0 to 100 or choose one number from the
range. This made it challenging for rating and giving weights to a
particular domain.
In conclusion, the PGI-HIV was used to measure the individual
quality of life in a Thai sample of HIV-positive patients for theﬁrst time. Their quality of life was mostly affected by the adverse
effects of ARV drugs, HIV symptoms, psychological problems, and
multiple drug therapy. In addition, patients were concerned
about ﬁnancial and social effects. It is the ﬁrst time that this
study reported the psychometric properties of the PGI-HIV, which
proves to be practical, highly reliable, and very responsive to
changes in patients’ quality of life, but not valid when compared
with HIV clinical variables. Further research is needed to conﬁrm
the psychometric properties of the PGI-HIV in other HIV patient
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